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Pharmacology of Warfarin
Mechanism of Action of Coumarin
Anticoagulant Drugs
Warfarin, a coumarin derivative, produces an anticoagulant
effect by interfering with the cyclic interconversion of vita-
min K and its 2,3 epoxide (vitamin K epoxide). Vitamin K is
a cofactor for the carboxylation of glutamate residues to
-carboxyglutamates (Gla) on the N-terminal regions of
vitamin K–dependent proteins (Figure 1) (1–6). These pro-
teins, which include the coagulation factors II, VII, IX, and X,
require -carboxylation by vitamin K for biological activity.
By inhibiting the vitamin K conversion cycle, warfarin
induces hepatic production of partially decarboxylated pro-
teins with reduced coagulant activity (7,8).
Carboxylation promotes binding of the vitamin K–depen-
dent coagulation factors to phospholipid surfaces, thereby
accelerating blood coagulation (9–11). -Carboxylation re-
quires the reduced form of vitamin K (vitamin KH2). Cou-
marins block the formation of vitamin KH2 by inhibiting the
enzyme vitamin K epoxide reductase, thereby limiting the
-carboxylation of the vitamin K–dependent coagulant pro-
teins. In addition, the vitamin K antagonists inhibit carboxy-
lation of the regulatory anticoagulant proteins C and S. The
anticoagulant effect of coumarins can be overcome by low
doses of vitamin K1 (phytonadione) because vitamin K1
bypasses vitamin K epoxide reductase (Figure 1). Patients
treated with large doses of vitamin K1 (usually 5 mg) can
become resistant to warfarin for up to a week because vitamin
K1 accumulating in the liver is available to bypass vitamin K
epoxide reductase.
Warfarin also interferes with the carboxylation of Gla
proteins synthesized in bone (12–15). Although these effects
contribute to fetal bone abnormalities when mothers are
treated with warfarin during pregnancy (16,17), there is no
evidence that warfarin directly affects bone metabolism when
administered to children or adults.
Pharmacokinetics and Pharmacodynamics
of Warfarin
Warfarin is a racemic mixture of 2 optically active isomers,
the R and S forms, in roughly equal proportion. It is rapidly
absorbed from the gastrointestinal tract, has high bioavail-
ability (18,19), and reaches maximal blood concentrations in
healthy volunteers 90 minutes after oral administration
(18,20). Racemic warfarin has a half-life of 36 to 42 hours
(21), circulates bound to plasma proteins (mainly albumin),
and accumulates in the liver, where the 2 isomers are
metabolically transformed by different pathways (21). The
relationship between the dose of warfarin and the response is
influenced by genetic and environmental factors, including
common mutations in the gene coding for cytochrome P450,
the hepatic enzyme responsible for oxidative metabolism of
the warfarin S-isomer (18,19). Several genetic polymor-
phisms in this enzyme have been described that are associated
with lower dose requirements and higher bleeding complica-
tion rates compared with the wild-type enzyme CYP2C9*
(22–24).
In addition to known and unknown genetic factors, drugs,
diet, and various disease states can interfere with the response
to warfarin.
The anticoagulant response to warfarin is influenced both
by pharmacokinetic factors, including drug interactions that
affect its absorption or metabolic clearance, and by pharma-
codynamic factors, which alter the hemostatic response to
given concentrations of the drug. Variability in anticoagulant
response also results from inaccuracies in laboratory testing,
patient noncompliance, and miscommunication between the
patient and physician. Other drugs may influence the phar-
macokinetics of warfarin by reducing gastrointestinal absorp-
tion or disrupting metabolic clearance. For example, the
anticoagulant effect of warfarin is reduced by cholestyramine,
which impairs its absorption, and is potentiated by drugs that
inhibit warfarin clearance through stereoselective or nonse-
lective pathways (25,26). Stereoselective interactions may
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affect oxidative metabolism of either the S- or R-isomer of
warfarin (25,26). Inhibition of S-warfarin metabolism is more
important clinically because this isomer is 5 times more
potent than the R-isomer as a vitamin K antagonist (25,26).
Phenylbutazone (27), sulfinpyrazone (28), metronidazole
(29), and trimethoprim-sulfamethoxazole (30) inhibit clear-
ance of S-warfarin, and each potentiates the effect of warfarin
on the prothrombin time (PT). In contrast, drugs such as
cimetidine and omeprazole, which inhibit clearance of the
R-isomer, potentiate the PT only modestly in patients treated
with warfarin (26,29,31). Amiodarone inhibits the metabolic
clearance of both the S- and R-isomers and potentiates
warfarin anticoagulation (32). The anticoagulant effect is
inhibited by drugs like barbiturates, rifampicin, and carbam-
azepine, which increase hepatic clearance (31). Chronic
alcohol consumption has a similar potential to increase the
clearance of warfarin, but ingestion of even relatively large
amounts of wine has little influence on PT in subjects treated
with warfarin (33). For a more thorough discussion of the
effect of enzyme induction on warfarin therapy, the reader is
referred to a recent critical review (34).
Warfarin pharmacodynamics are subject to genetic and
environmental variability as well. Hereditary resistance to
warfarin occurs in rats as well as in human beings (35–37).
and patients with genetic warfarin resistance require doses 5-
to 20-fold higher than average to achieve an anticoagulant
effect. This disorder is attributed to reduced affinity of
warfarin for its hepatic receptor.
A mutation in the factor IX propeptide that causes bleeding
without excessive prolongation of PT also has been described
(38). The mutation occurs in 1.5% of the population.
Patients with this mutation experience a marked decrease in
factor IX during treatment with coumarin drugs, and levels of
other vitamin K–dependent coagulation factors decrease to
30% to 40%. The coagulopathy is not reflected in the PT, and
therefore, patients with this mutation are at risk of bleeding
during warfarin therapy (38–40). An exaggerated response to
warfarin among the elderly may reflect its reduced clearance
with age (41–43).
Subjects receiving long-term warfarin therapy are sensitive
to fluctuating levels of dietary vitamin K (44,45), which is
derived predominantly from phylloquinones in plant material
(45). The phylloquinone content of a wide range of foodstuffs
has been listed by Sadowski and associates (46). Phylloqui-
nones counteract the anticoagulant effect of warfarin because
they are reduced to vitamin KH2 through the warfarin-
insensitive pathway (47). Important fluctuations in vitamin K
intake occur in both healthy and sick subjects (48). Increased
intake of dietary vitamin K sufficient to reduce the anticoag-
ulant response to warfarin (44) occurs in patients consuming
green vegetables or vitamin K–containing supplements while
following weight-reduction diets and in patients treated with
intravenous vitamin K supplements. Reduced dietary vitamin
K1 intake potentiates the effect of warfarin in sick patients
treated with antibiotics and intravenous fluids without vita-
min K supplementation and in states of fat malabsorption.
Hepatic dysfunction potentiates the response to warfarin
through impaired synthesis of coagulation factors. Hypermet-
abolic states produced by fever or hyperthyroidism increase
warfarin responsiveness, probably by increasing the catabo-
lism of vitamin K–dependent coagulation factors (49,50).
Drugs may influence the pharmacodynamics of warfarin by
inhibiting synthesis or increasing clearance of vitamin K–de-
pendent coagulation factors or by interfering with other
pathways of hemostasis. The anticoagulant effect of warfarin
is augmented by the second- and third-generation cephalo-
sporins, which inhibit the cyclic interconversion of vitamin K
(51,52); by thyroxine, which increases the metabolism of
coagulation factors (50); and by clofibrate, through an un-
known mechanism (53). Doses of salicylates 1.5 g per day
(54) and acetaminophen (55) also augment the anticoagulant
effect of warfarin, possibly because these drugs have
warfarin-like activity (56). Heparin potentiates the anticoag-
ulant effect of warfarin but in therapeutic doses produces only
slight prolongation of the PT.
Drugs such as aspirin (57), nonsteroidal antiinflammatory
drugs (58), penicillins (in high doses) (59,60), and moxolac-
tam (52) increase the risk of warfarin-associated bleeding by
inhibiting platelet function. Of these, aspirin is the most
important because of its widespread use and prolonged effect
(61). Aspirin and nonsteroidal antiinflammatory drugs also
can produce gastric erosions that increase the risk of upper
gastrointestinal bleeding. The risk of clinically important
bleeding is heightened when high doses of aspirin are taken
Figure 1. The vitamin K cycle and its link to carboxylation of
glutamic acid residues on vitamin K–dependent coagulation
proteins. Vitamin K1 obtained from food sources is reduced to
vitamin KH2 by a warfarin-resistant vitamin K reductase. Vitamin
KH2 is then oxidized to vitamin K epoxide (Vit KO) in a reaction
that is coupled to carboxylation of glutamic acid residues on
coagulation factors. This carboxylation step renders the coagu-
lation factors II, VII, IX, and X and the anticoagulant factors pro-
tein C and protein S functionally active. Vit KO is then reduced
to Vit K1 in a reaction catalyzed by vitamin KO reductase. By
inhibiting vitamin KO reductase, warfarin blocks the formation of
vitamin K1 and vitamin KH2, thereby removing the substrate
(vitamin KH2) for the carboxylation of glutamic acids. Vitamin K1,
either given therapeutically or derived from food sources,
can overcome the effect of warfarin by bypassing the warfarin-
sensitive vitamin KO reductase step in the formation of
vitamin KH2.
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during high-intensity warfarin therapy (international normal-
ized ratio [INR] 3.0 to 4.5) (57,62). In 2 studies, one
involving patients with prosthetic heart valves (63) and the
other involving asymptomatic individuals at high risk of
coronary artery disease (64), low doses of aspirin (100 mg
and 75 mg daily, combined with moderate- and low-intensity
warfarin anticoagulation, respectively) also were associated
with increased rates of minor bleeding.
The mechanisms by which erythromycin (65) and some
anabolic steroids (66) potentiate the anticoagulant effect of
warfarin are unknown. Sulfonamides and several broad-
spectrum antibiotic compounds may augment the anticoagu-
lant effect of warfarin in patients consuming diets deficient in
vitamin K by eliminating bacterial flora and aggravating
vitamin K deficiency (67).
Wells et al (68) critically analyzed reports of possible
interactions between drugs or foods and warfarin. Interactions
were categorized as highly probable, probable, possible, or
doubtful. There was strong evidence of interaction in 39 of
the 81 different drugs and foods appraised; 17 potentiate
warfarin effect and 10 inhibit it, but 12 produce no effect.
Many other drugs have been reported to either interact with
oral anticoagulants or alter the PT response to warfarin
(69,70). A recent review highlighted the importance of
postmarketing surveillance with newer drugs, such as cele-
coxib, a drug that showed no interactions in Phase 2 studies
but was subsequently suspected of potentiating the effect of
warfarin in several case reports (71). This review also drew
attention to potential interactions with less well-regulated
herbal medicines. For these reasons, the INR should be
measured more frequently when virtually any drug or herbal
medicine is added or withdrawn from the regimen of a patient
treated with warfarin.
The Antithrombotic Effect of Warfarin
The antithrombotic effect of warfarin conventionally has
been attributed to its anticoagulant effect, which in turn is
mediated by the reduction of 4 vitamin K–dependent coag-
ulation factors. More recent evidence, however, suggests that
the anticoagulant and antithrombotic effects can be dissoci-
ated and that reduction of prothrombin and possibly factor X
are more important than reduction of factors VII and IX for
the antithrombotic effect. This evidence is indirect and
derived from the following observations: First, the experi-
ments of Wessler and Gitel (72) more than 40 years ago,
which used a stasis model of thrombosis in rabbits, showed
TABLE 1. Capillary Whole Blood (Point-of-Care) PT Instruments
Instrument
Clot Detection
Methodology
Type of
Sample
Home Use
Approval
Protime Monitor 1000
Coumatrak*
Ciba Corning 512 Coagulation Monitor*
CoaguChek Plus*
CoaguChek Pro*
CoaguChek Pro/DM*
Clot initiation: Thromboplastin
Clot detection: Cessation of blood flow through
capillary channel
Capillary WB
Venous WB
No
CoaguChek
CoaguChek S
Thrombolytic Assessment System
Rapidpoint Coag
Clot initiation: Thromboplastin
Clot detection: Cessation of movement of iron
particles
Capillary WB
Venous WB Plasma
Yes†
(CoaguChek
only)
ProTIME Monitor
Hemochron Jr‡
GEM PCL‡
Clot initiation: Thromboplastin
Clot detection: Cessation of blood flow through
capillary channel
Capillary WB
Venous WB
Yes
Avosure Pro§
Avosure Pro§
Avosure PT§
Clot initiation: Thromboplastin
Clot detection: Thrombin generations detected
by fluorescent thrombin probe
Capillary WB
Venous WB Plasma
Yes
Harmony Clot initiation: Thromboplastin
Clot detection: Cessation of blood flow through
capillary channel
Capillary WB
Venous WB
Yes
INRatio Clot initiation: Thromboplastin
Clot detection: Change in impedance in sample
Capillary WB
Venous WB
Yes
WB indicates whole blood.
*All instruments in this category are based on the original Biotrack model (Protime Monitor 1000) and licensed under different
names. The latest version available is the CoaguChek Pro and Pro/DM (as models evolved, they acquired added capabilities); earlier
models are no longer available.
†CoaguChek not actively marketed for home use at the time of this writing. Thrombolytic Assessment System not available for home
use.
‡Hemochron Jr and GEM PCL are simplified versions of the ProTIME Monitor.
§Avosure instruments removed from market when manufacturer (Avocet, Inc) ceased operations (2001). Technology has since been
purchased by Beckman Coulter.
INRange system manufactured by Hemosense, Inc, is currently in development.
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that the antithrombotic effect of warfarin requires 6 days of
treatment, whereas an anticoagulant effect develops in 2. The
antithrombotic effect of warfarin requires reduction of pro-
thrombin (factor II), which has a relatively long half-life of
60 to 72 hours, compared with 6 to 24 hours for other
K-dependent factors responsible for the more rapid anticoag-
ulant effect. Second, in a rabbit model of tissue factor–
induced intravascular coagulation, the protective effect of
warfarin is mainly a result of lowering prothrombin levels
(73). Third, Patel and associates (74) demonstrated that clots
formed from umbilical cord plasma (containing about half the
prothrombin concentration of adult control plasma) generated
significantly less fibrinopeptide A, reflecting less thrombin
activity, than clots formed from maternal plasma. The view
that warfarin exerts its antithrombotic effect by reducing
prothrombin levels is consistent with observations that clot-
bound thrombin is an important mediator of clot growth (75)
and that reduction in prothrombin levels decreases the
amount of thrombin generated and bound to fibrin, reducing
thrombogenicity (74).
The suggestion that the antithrombotic effect of warfarin is
reflected in lower levels of prothrombin forms the basis for
overlapping heparin with warfarin until the PT (INR) is
prolonged into the therapeutic range during treatment of
patients with thrombosis. Because the half-life of prothrom-
bin is 60 to 72 hours, 4 days’ overlap is necessary.
Furthermore, the levels of native prothrombin antigen during
warfarin therapy more closely reflect antithrombotic activity
than the PT (76). These considerations support administering
a maintenance dose of warfarin (5 mg daily) rather than a
loading dose when initiating therapy. The rate of lowering
prothrombin levels was similar with either a 5- or a 10-mg
initial warfarin dose (77), but the anticoagulant protein C was
reduced more rapidly and more patients were excessively
anticoagulated (INR 3.0) with a 10-mg loading dose.
Management of Oral Anticoagulant Therapy
Monitoring Anticoagulation Intensity
The PT is the most common test used to monitor oral
anticoagulant therapy (78). The PT responds to reduction of 3
of the 4 vitamin K–dependent procoagulant clotting factors
(II, VII, and X) that are reduced by warfarin at a rate
proportionate to their respective half-lives. Thus, during the
first few days of warfarin therapy, the PT reflects mainly
reduction of factor VII, the half-life of which is 6 hours.
Subsequently, reduction of factors X and II contributes to
prolongation of the PT. The PT assay is performed by adding
calcium and thromboplastin to citrated plasma. The tradi-
tional term “thromboplastin” refers to a phospholipid-protein
extract of tissue (usually lung, brain, or placenta) that
contains both the tissue factor and phospholipid necessary to
promote activation of factor X by factor VII. Thromboplas-
tins vary in responsiveness to the anticoagulant effects of
warfarin according to their source, phospholipid content, and
preparation (79–81). The responsiveness of a given throm-
boplastin to warfarin-induced changes in clotting factors
reflects the intensity of activation of factor X by the factor
VIIa/tissue factor complex. An unresponsive thromboplastin
produces less prolongation of the PT for a given reduction in
vitamin K–dependent clotting factors than a responsive one.
The responsiveness of a thromboplastin can be measured by
assessing its International Sensitivity Index (ISI) (see below).
PT monitoring of warfarin treatment is very imprecise
when expressed as a PT ratio (calculated as a simple ratio of
the patient’s plasma value over that of normal control plasma)
because thromboplastins can vary markedly in their respon-
siveness to warfarin. Differences in thromboplastin respon-
siveness contributed to clinically important differences in oral
anticoagulant dosing among countries (82) and were respon-
sible for excessive and erratic anticoagulation in North
America, where less responsive as well as responsive throm-
boplastins were in common use. Recognition of these short-
comings in PT monitoring stimulated the development of the
INR standard for monitoring oral anticoagulant therapy, and
the adoption of this standard improved the safety of oral
anticoagulant therapy and its ease of monitoring.
The history of standardization of the PT has been reviewed
by Poller (80) and by Kirkwood (83). In 1992, the ISI of
thromboplastins used in the United States varied between 1.4
and 2.8 (84). Subsequently, more responsive thromboplastins
with lower ISI values have come into clinical use in the
United States and Canada. For example, the recombinant
human preparations consisting of relipidated synthetic tissue
factor have ISI values of 0.9 to 1.0 (85). The INR calibration
model, adopted in 1982, is now used to standardize reporting
by converting the PT ratio measured with the local thrombo-
plastin into an INR, calculated as follows:
INR  (patient PT/mean normal PT)ISI
or
log INR  ISI (log observed PT ratio),
where ISI denotes the International Sensitivity Index of the
thromboplastin used at the local laboratory to perform the PT
measurement. The ISI reflects the responsiveness of a given
thromboplastin to reduction of the vitamin K–dependent
coagulation factors. The more responsive the reagent, the
lower the ISI value (80,83,86).
Most commercial manufacturers provide ISI values for
thromboplastin reagents, and the INR standard has been
widely adopted by hospitals in North America. Thromboplas-
tins with recombinant tissue factor have been introduced with
ISI values close to 1.0, yielding PT ratios virtually equivalent
to the INR. According to the College of American Patholo-
gists Comprehensive Coagulation Survey, implementation of
the INR standard in the United States increased from 21% to
97% between 1991 and 1997 (82). As the INR standard of
reporting was widely adopted, however, several problems
surfaced. These are reviewed briefly below.
As noted above, the INR is based on ISI values derived
from plasma of patients on stable anticoagulant doses for 6
weeks (87). As a result, the INR is less reliable early in the
course of warfarin therapy, particularly when results are
obtained from different laboratories. Even under these con-
ditions, however, the INR is more reliable than the uncon-
verted PT ratio (88) and is thus recommended during both
initiation and maintenance of warfarin treatment. There is
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also evidence that the INR is a reliable measure of impaired
blood coagulation in patients with liver disease (89).
Theoretically, the INR could be made more precise by
using reagents with low ISI values, but laboratory proficiency
studies indicate that this produces only modest improvement
(90–93), whereas reagents with higher ISI values result in
higher coefficients of variation (94,95). Variability of ISI
determination is reduced by calibrating the instrument with
lyophilized plasma depleted of vitamin K–dependent clotting
factors (95–97). Because the INR is based on a mathematical
relationship using a manual method for clot detection, the
accuracy of the INR measurement can be influenced by the
automated clot detectors now used in most laboratories
(98–103). In general, the College of American Pathologists
has recommended that laboratories use responsive thrombo-
plastin reagents (ISI 1.7) and reagent/instrument combina-
tions for which the ISI has been established (104).
ISI values provided by manufacturers of thromboplastin
reagents are not invariably correct (105–107), and this ad-
versely affects the reliability of measurements. Local calibra-
tions can be performed by using plasma samples with
certified PT values to determine the instrument-specific ISI.
The mean normal plasma PT is determined from fresh plasma
samples from 20 healthy individuals and is not interchange-
able with a laboratory control PT (108). Because the distri-
bution of PT values is not normal, log-transformation and
calculation of a geometric mean are recommended. The mean
normal PT should be determined with each new batch of
thromboplastin with the same instrument used to assay the PT
(108).
The concentration of citrate used to anticoagulate plasma
affects the INR (109,110). In general, higher citrate concen-
trations (3.8%) lead to higher INR values (109), and
underfilling the blood collection tube spuriously prolongs the
PT because excess citrate is present. Using collection tubes
containing 3.2% citrate for blood coagulation studies can
reduce this problem.
The lupus anticoagulants prolong the activated partial
thromboplastin time but usually cause only slight prolonga-
tion of the PT, according to the reagents used (111,112). The
prothrombin and proconvertin tests (113,114) and measure-
ments of prothrombin activity or native prothrombin concen-
tration have been proposed as alternatives (76,114–116), but
the optimum method for monitoring anticoagulation in pa-
tients with lupus anticoagulants is uncertain.
Practical Warfarin Dosing and Monitoring
Warfarin dosing may be separated into initial and mainte-
nance phases. After treatment is started, the INR response is
monitored frequently until a stable dose-response relationship
is obtained; thereafter, the frequency of INR testing is
reduced.
An anticoagulant effect is observed within 2 to 7 days after
beginning oral warfarin, according to the dose administered.
When a rapid effect is required, heparin should be given
concurrently with warfarin for 4 days. The common prac-
tice of administering a loading dose of warfarin is generally
unnecessary, and there are theoretical reasons for beginning
treatment with the average maintenance dose of 5 mg daily,
which usually results in an INR of 2.0 after 4 or 5 days.
Heparin usually can be stopped once the INR has been in the
therapeutic range for 2 days. When anticoagulation is not
urgent (eg, chronic atrial fibrillation), treatment can be
commenced out of hospital with a dose of 4 to 5 mg/d, which
usually produces a satisfactory anticoagulant effect within 6
days (77). Starting doses 4 to 5 mg/d should be used in
patients sensitive to warfarin, including the elderly (40,117),
and in those at increased risk of bleeding.
The INR is usually checked daily until the therapeutic
range has been reached and sustained for 2 consecutive days,
then 2 or 3 times weekly for 1 to 2 weeks, then less often,
according to the stability of the results. Once the INR
becomes stable, the frequency of testing can be reduced to
intervals as long as 4 weeks. When dose adjustments are
required, frequent monitoring is resumed. Some patients on
long-term warfarin therapy experience unexpected fluctua-
tions in dose-response due to changes in diet, concurrent
medication changes, poor compliance, or alcohol
consumption.
The safety and effectiveness of warfarin therapy depends
critically on maintaining the INR within the therapeutic
range. On-treatment analysis of the primary prevention trials
in atrial fibrillation found that a disproportionate number of
thromboembolic and bleeding events occurred when the PT
ratio was outside the therapeutic range (118). Subgroup
analyses of other cohort studies also have shown a sharp
increase in the risk of bleeding when the INR is higher than
the upper limit of the therapeutic range (116,119–122), and
the risk of thromboembolism increased when the INR fell to
2.0 (123,124).
Point-of-Care Patient Self-Testing
Point-of-care (POC) PT measurements offer the potential for
simplifying oral anticoagulation management in both the
physician’s office and the patient’s home. POC monitors
measure a thromboplastin-mediated clotting time that is
converted to plasma PT equivalent by a microprocessor and
expressed as either the PT or the INR. The original method-
ology was incorporated into the Biotrack instrument
(Coumatrak; Biotrack, Inc) evaluated by Lucas et al (125) in
1987. These investigators reported a correlation coefficient
(r) of 0.96 between reference plasma PT and capillary whole
blood PT, findings that were confirmed in other studies (126).
By early 2000, the US Food and Drug Administration
(FDA) had approved 3 monitors for patient self-testing at
home (127), but each instrument has limitations. Instruments
currently marketed for this purpose are listed in Table 1. In a
study (128) in which a derivative of the Biotrack monitor
(Biotrack 512; Ciba-Corning) was used, the POC instrument
compared poorly with the Thrombotest, the former underes-
timating the INR by a mean of 0.76. Another Biotrack
derivative (Coumatrak; DuPont) was accurate in an INR
range of 2.0 to 3.0 but gave discrepant results at higher INR
values (129). In another study, the Ciba-Corning monitor
underestimated the results when the INR was 4.0, but the
error was overcome by using a revised ISI value to calculate
the INR (130). Several investigators (131–133) reported
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excellent correlations with reference plasma PT values when
a second category of monitor (CoaguChek; Roche Diagnos-
tics, Inc) was used. The ISI calibration with this system,
based on an international reference preparation, was ex-
tremely close to indices adopted by the manufacturer for both
whole blood and plasma (134). Both classes of monitors
(Biotrack and Coagu-Chek) compared favorably with tradi-
tionally obtained PT measurements at 4 laboratories and with
TABLE 3. Relationship Between Anticoagulation Intensity and Bleeding
Source
No. of
Patients
Duration of
Therapy Target INR Range
Incidence of
Bleeding, % P
Hull et al 1982167—deep vein thrombosis 96 3 mo 3.0–4.5 vs 2.0–2.5 22.4 vs 4.3 0.015
Turpie et al 1988168—prosthetic heart valves (tissue) 210 3 mo 2.5–4.0 vs 2.0–2.5 13.9 vs 5.9 0.002
Saour et al 1990169—mechanical prosthetic heart valves 247 3.47 y 7.4–10.8 vs 1.9–3.6 42.4 vs 21.3 0.002
Altman et al 1991170—mechanical prosthetic heart valves* 99 11.2 mo 3.0–4.5 vs 2.0–2.9 24.0 vs 6.0 0.02
*Patients also given aspirin 300 mg daily, and dipyridamole 75 mg BID.
TABLE 2. Studies of Patient Self-Testing and Self-Management of Anticoagulation
Study Study Design
Study
Groups
No. of
Patients
Time in Range,
% INR
% Time
Major Hemorrhage,
% per patient-year
Thromboembolism,
% per patient-year Indications
White140 1989 RCT
PST 23 93 0 0 Mixed
AMS 23 75 0 0 Mixed
Anderson139 1993 Inception cohort
PST 40 74 0 0 Mixed
Beyth141 1997 RCT
PST 162 56 5.7 9 Mixed
UC 163 33 12 13 Mixed
Ansell145 1995 Observational cohort
PSM 20 89 0 0 Mixed
AMS 20 68 0 0 Mixed
Bernardo146 1996 Observational
PSM 216 83 NA NA Heart valves
Horstkotte147 1996 RCT
PSM 75 92 4.5* 0.9 Heart valves
UC 75 59 10.9* 3.6 Heart valves
Hasenkam142 1997 Observational
matched control
PSM 20 77 NA NA Heart valves
UC 20 53 NA NA Heart valves
Sawicki148 1999 RCT
PSM 90 57/53† 2.2 2.2 Mixed
UC 89 34/43† 2.2 4.5 Mixed
Kortke149 2001 RCT
PSM 305 78 1.7 1.2 Mixed
UC 295 60 2.6 2.1 Mixed
Watzke150 2000 Prospective controlled
PSM 49 86 4‡ 0 Mixed
ACC 53 80 0 0 Mixed
Cromheecke151 2000 Randomized crossover
PSM 50 55 0 0 Mixed
ACC 50 49 0 16 Mixed
RCT indicates randomized controlled trial; PST, patient self-testing; PSM, patient self-management; AMS, anticoagulation management service; UC,
usual care; and Mixed, mixed indications.
*Major and minor bleeding.
†Time in target range at 3 and 6 mo.
‡Percentage of episodes in 49 patients.
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the standard manual tilt-tube technique established by the
World Health Organization using an international reference
thromboplastin (135). Laboratories using a more sensitive
thromboplastin showed close agreement with the standard,
whereas agreement was poor when insensitive thromboplas-
tins were used; INR determinations with the Coumatrak and
CoaguChek monitors were only slightly less accurate than the
conventional method used in the best clinical laboratories.
A third category of POC capillary whole blood PT instru-
ments (ProTIME Monitor; International Technidyne Corpo-
ration) differs from the other 2 types of instruments in that it
performs a PT in triplicate (3 capillary channels) and simul-
taneously performs level 1 and level 2 controls (2 additional
capillary channels). In a multiinstitutional trial (136), the
instrument INR correlated well with reference laboratory
tests and those performed by a healthcare provider (venous
sample, r0.93; capillary sample, r0.93; patient finger-
stick, r0.91). In a separate report involving 76 warfarin-
treated children and 9 healthy control subjects, the coefficient
of correlation between venous and capillary samples was
0.89. Compared with venous blood tested in a reference
laboratory (ISI1.0), correlation coefficients were 0.90 and
0.92, respectively (137). Published results with a fourth type
of PT monitor (Avocet PT 1000) in 160 subjects demonstrate
good correlation when compared with reference laboratory
INR values with capillary blood, citrated venous whole
blood, and citrated venous plasma (r0.97, 0.97, and 0.96,
respectively) (138).
The feasibility and accuracy of patient self-testing at home
initially was evaluated in 2 small studies with promising
results (139,140). More recently, Beyth and Landefeld (141)
randomized 325 newly treated elderly patients to either
conventional treatment by personal physicians based on
venous sampling or adjustment of dosage by a central
investigator based on INR results from patient self-testing at
home. Over a 6-month period, the rate of hemorrhage was
12% in the usual-care group compared with 5.7% in the
self-testing group. These and other studies in which patient
self-testing and self-management of anticoagulation have
been evaluated are summarized in Table 2 (142).
Patient Self-Management
Coupled with self-testing, self-management with the use of
POC instruments offers independence and freedom of travel
to selected patients. The feasibility of initial patient self-
management of oral anticoagulation was demonstrated in
several studies (143–146). These descriptive studies were
then followed by several randomized trials. In the first study,
75 patients with prosthetic heart valves who managed their
own therapy were compared with a control group of the same
size managed by their personal physicians (147). The self-
managed patients tested themselves approximately every 4
days and achieved a 92% degree of satisfactory anticoagula-
tion, as determined by the INR. The physician-managed
patients were tested approximately every 19 days, but only
59% of INR values were in therapeutic range. Self-managed
individuals experienced a 4.5% per year incidence of bleed-
ing of any severity and a 0.9% per year rate of thromboem-
bolism, compared with 10.9% and 3.6%, respectively, in the
physician-managed group (P0.05 between groups). An-
other comparison of self-management (n90) with usual care
(n89) (148) found that the difference in the percentage of
INR values within the therapeutic range at 3 months became
statistically insignificant at 6 months. Results from the large,
randomized Early Self-Controlled Anticoagulation Study in
Germany (ESCAT) (149) showed that among 305 self-
managed patients, INR values were more frequently in range
(78%) compared with 61% in 295 patients assigned to usual
care. The rate of major adverse events was significantly
different between groups: 2.9% per patient-year of therapy in
the self-managed group versus 4.7% in the usual-care group
(P0.042).
When patient self-management is compared with the out-
comes of high-quality anticoagulation management delivered
by an anticoagulation clinic, the differences between the 2
methods of management are less marked. Watzke et al (150)
compared weekly INR patient self-management in 49 patients
with management by an anticoagulation clinic in 53 patients.
There was no significant difference for time in therapeutic
range between groups, but the self-management group had a
significantly smaller mean deviation from their target INR.
Cromheecke et al (151) conducted a randomized crossover
study with 50 patients managed by an anticoagulation clinic
or by self-management. Although the differences did not
achieve statistical significance, there was a trend toward
greater time in therapeutic range in the self-management
group (55% versus 49%).
Preliminary results from 2 recent studies further suggest
that when compared with anticoagulation clinic management,
patient self-testing or patient self-management offers limited
advantages. Both Gadisseur et al (152) and Kaatz et al (153)
found that time in therapeutic range was the same regardless
of whether patients self-tested and self-managed or were
managed by an anticoagulation clinic.
Computerized Algorithms for Warfarin
Dose Adjustment
Several computer programs have been developed to guide
warfarin dosing. They are based on various techniques:
querying physicians (154), Bayesian forecasting (155), and a
proprietary mathematical equation (156). In general, the latter
involve fixed-effects log-linear Bayesian modeling, which
accounts for factors unique to each measurement. The re-
sponse variance not explained by previous warfarin dose and
previous INR values is specific and constant over time for
each patient but not entirely accounted for mathematically. In
one randomized trial, the reliability of 3 established comput-
erized dosage programs were compared with warfarin dosing
by experienced medical staff in an outpatient clinic (157).
Control was similar with the computer-guided and empirical
dose adjustments in the INR range of 2.0 to 3.0, but the
computer programs achieved significantly better control
when more intensive therapy (INR 3.0 to 4.5) was required.
In another randomized study of 101 chronically anticoagu-
lated patients with prosthetic cardiac valves, computerized
warfarin adjustments proved comparable to manual regula-
tion in the percentage of INR values kept within the thera-
peutic range but required 50% fewer dose adjustments (158).
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A multicenter randomized study of 285 patients found
computer-assisted dose regulation more effective than tradi-
tional dosing at maintaining therapeutic INR values. Taken
together, these data suggest that computer-guided warfarin
dose adjustment is superior to traditional dose regulation,
particularly when personnel are inexperienced.
Management of Patients With High INR Values
There is a close relation between the INR and risk of bleeding
(Table 1). The risk of bleeding increases when the INR
exceeds 4, and the risk rises sharply with values 5. Three
approaches can be taken to lower an elevated INR. The first
step is to stop warfarin; the second is to administer vitamin
K1; and the third and most rapidly effective measure is to
infuse fresh plasma or prothrombin concentrate. The choice
of approach is based largely on clinical judgment because no
randomized trials have compared these strategies with clini-
cal end points. After warfarin is interrupted, the INR falls
over several days (an INR between 2.0 and 3.0 falls to the
normal range 4 to 5 days after warfarin is stopped) (159). In
contrast, the INR declines substantially within 24 hours after
treatment with vitamin K1 (160).
Even when the INR is excessively prolonged, the absolute
daily risk of bleeding is low, leading many physicians to
manage patients with INR levels as high as 5 to 10 by
stopping warfarin expectantly, unless the patient is at intrin-
sically high risk of bleeding or bleeding has already devel-
oped. Ideally, vitamin K1 should be administered in a dose
that will quickly lower the INR into a safe but not subthera-
peutic range without causing resistance once warfarin is
reinstated or exposing the patient to the risk of anaphylaxis.
Though effective, high doses of vitamin K1 (eg, 10 mg) may
lower the INR more than necessary and lead to warfarin
resistance for up to a week. Vitamin K1 can be administered
intravenously, subcutaneously, or orally. Intravenous injec-
tion produces a rapid response but may be associated with
anaphylactic reactions, and there is no proof that this rare but
serious complication can be avoided by using low doses. The
response to subcutaneous vitamin K1 is unpredictable and
sometimes delayed (161,162). In contrast, oral administration
is predictably effective and has the advantages of conve-
nience and safety over parenteral routes. In patients with
excessively prolonged INR values, vitamin K1, 1 mg to 2.5
mg orally, more rapidly lowers the INR to 5 within 24
hours than simply withholding warfarin (163). In a prospec-
tive study of 62 warfarin-treated patients with INR values
between 4 and 10, warfarin was omitted, and vitamin K1, 1
mg, was administered orally (162,164). After 24 hours, the
INR was lower in 95%, 4 in 85%, and 1.9 in 35%. None
displayed resistance when warfarin was resumed. These
observations indicate that oral vitamin K1 in low doses
effectively reduces the INR in patients treated with warfarin.
Oral vitamin K1, 1.0 to 2.5 mg, is sufficient when the INR is
between 4 and 10, but larger doses (5 mg) are required when
the INR is 10.
Oral vitamin K1 is the treatment of choice unless very rapid
reversal of anticoagulation is critical, when vitamin K1 can be
administered by slow intravenous infusion (5 to 10 mg over
30 minutes). In 2001, the American College of Chest Physi-
cians published the following recommendations for managing
patients on coumarin anticoagulants who need their INRs
lowered because of either actual or potential bleeding (164):
(1) When the INR is above the therapeutic range but 5,
the patient has not developed clinically significant
bleeding, and rapid reversal is not required for surgical
intervention, the dose of warfarin can be reduced or the
next dose omitted and resumed (at a lower dose) when
the INR approaches the desired range.
(2) If the INR is between 5 and 9 and the patient is not
bleeding and has no risk factors that predispose to
bleeding, the next 1 or 2 doses of warfarin can be
omitted and warfarin reinstated at a lower dose when
the INR falls into the therapeutic range. Alternatively,
the next dose of warfarin may be omitted and vitamin
K1 (1 to 2.5 mg) given orally. This approach should be
used if the patient is at increased risk of bleeding.
(3) When more rapid reversal is required to allow urgent
surgery or dental extraction, vitamin K1 can be given
orally in a dose of 2 to 5 mg, anticipating reduction of
the INR within 24 hours. An additional dose of 1 or 2
mg vitamin K can be given if the INR remains high
after 24 hours.
(4) If the INR is 9 but clinically significant bleeding has
not occurred, vitamin K1, 3 to 5 mg, should be given
orally, anticipating that the INR will fall within 24 to
48 hours. The INR should be monitored closely and
vitamin K repeated as necessary.
(5) When rapid reversal of anticoagulation is required
because of serious bleeding or major warfarin over-
dose (eg, INR 20), vitamin K1 should be given by
slow intravenous infusion in a dose of 10 mg, supple-
mented with transfusion of fresh plasma or prothrom-
bin complex concentrate, according to the urgency of
the situation. It may be necessary to give additional
doses of vitamin K1 every 12 hours.
(6) In cases of life-threatening bleeding or serious warfa-
rin overdose, prothrombin complex concentrate re-
placement therapy is indicated, supplemented with 10
mg of vitamin K1 by slow intravenous infusion; this
can be repeated, according to the INR. If warfarin is to
be resumed after administration of high doses of
vitamin K, then heparin can be given until the effects
of vitamin K have been reversed and the patient again
becomes responsive to warfarin.
Bleeding During Oral Anticoagulant Therapy
The main complication of oral anticoagulant therapy is
bleeding, and risk is related to the intensity of anticoagulation
(Table 3) (165–170). Other contributing factors are the
underlying clinical disorder (165,171) and concomitant ad-
ministration of aspirin, nonsteroidal antiinflammatory drugs,
or other drugs that impair platelet function, produce gastric
erosions, and in very high doses impair synthesis of vitamin
K–dependent clotting factors (57,60,62). The risk of major
bleeding also is related to age 65 years, a history of stroke
or gastrointestinal bleeding, and comorbid conditions such as
renal insufficiency or anemia (164,165). These risk factors
are additive; patients with 2 or 3 risk factors have a much
higher incidence of warfarin-associated bleeding that those
with none or one (172). The elderly are more prone to
bleeding even after controlling for anticoagulation intensity
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(118,167). Bleeding that occurs at an INR of 3.0 is
frequently associated with trauma or an underlying lesion in
the gastrointestinal or urinary tract (165).
Four randomized studies have demonstrated that lowering
the INR target range from 3.0 to 4.5 to 2.0 to 3.0 reduces the
risk of clinically significant bleeding (167–169). Although
this difference in anticoagulant intensity is associated with an
average warfarin dose reduction of only 1 mg/d, the effect
on bleeding risk is impressive. It is prudent to initiate
warfarin at lower doses in the elderly, as patients 75 years
of age require 1 mg/d less than younger individuals to
maintain comparable prolongation of the INR.
Long-term management is challenging for patients who
have experienced bleeding during warfarin anticoagulation
yet require thromboembolic prophylaxis (eg, those with
mechanical heart valves or high-risk patients with atrial
fibrillation). If bleeding occurred when the INR was above
the therapeutic range, warfarin can be resumed once bleeding
has stopped and its cause corrected. For patients with me-
chanical prosthetic heart valves and persistent risk of bleed-
ing during anticoagulation in the therapeutic range, a target
INR of 2.0 to 2.5 seems sensible. For those in this situation
with atrial fibrillation, anticoagulant intensity can be reduced
to an INR of 1.5 to 2.0, anticipating that efficacy will be
diminished but not abolished (123). In certain subgroups of
patients with atrial fibrillation, aspirin may be an appropriate
alternative to warfarin (173).
Management of Anticoagulated Patients Who
Require Surgery
The management of patients treated with warfarin who
require interruption of anticoagulation for surgery or other
invasive procedures can be problematic. Several approaches
can be taken, according to the risk of thromboembolism
(174). In most patients, warfarin is stopped 4 to 5 days
preoperatively, thereby allowing the INR to return to normal
(1.2) at the time of the procedure. Such patients remain
unprotected for 2 to 3 days preoperatively. The period off
warfarin can be reduced to 2 days by giving vitamin K1, 2.5
mg orally, 2 days before the procedure with the expectation
that the patient will remain unprotected for 2 days and that
the INR will return to normal at the time of the procedure.
Heparin can be given preoperatively to limit the period of
time that the patient remains unprotected, and anticoagulant
therapy can be recommenced postoperatively once it is
deemed to be safe to restart treatment. Low-molecular-weight
heparin (LMWH) can be used instead of heparin, but infor-
mation on its efficacy in patients with prosthetic heart valves
who require intercurrent surgery is lacking.
Moreover, the FDA and Aventis strengthened the “Warn-
ing” and “Precautions” sections of the Lovenox prescribing
information to inform health professionals that the use of
Lovenox injection is not recommended for thromboprophy-
laxis in patients with prosthetic heart valves.
● For patients at moderate risk of thromboembolism, preop-
erative heparin in prophylactic doses of 5000 U (or LMWH
in prophylactic doses of 3000 U) can be given subcutane-
ously every 12 hours. Heparin (or LMWH) in these
prophylactic doses can be restarted 12 hours postopera-
tively along with warfarin and the combination continued
for 4 to 5 days until the INR returns to the desired range. If
patients are considered to be at high risk of postoperative
bleeding, heparin or LMWH can be delayed for 24 hours or
longer.
● For patients at high risk of thromboembolism, low doses of
heparin or LMWH might not provide adequate protection
after warfarin is discontinued preoperatively, and these
high-risk patients should be treated with therapeutic doses
of heparin (15 000 U every 12 hours by subcutaneous
injection) or LMWH (100 U/kg every 12 hours by subcu-
taneous injection). These anticoagulants can be adminis-
tered on an ambulatory basis or in hospital and discontin-
ued 24 hours before surgery with the expectation that their
effect will last until 12 hours before surgery. If maintaining
preoperative anticoagulation is considered to be critical, the
patient can be admitted to hospital, and heparin can be
administered in full doses (1300 U/h) by continuous
intravenous infusion and stopped 5 hours before surgery,
allowing the activated partial thromboplastin time to return
to baseline at the time of the procedure. Heparin or LMWH
can then be restarted in prophylactic doses 12 hours
postoperatively along with warfarin and continued until the
INR reaches the desired range.
● For patients at low risk of thromboembolism (eg, atrial
fibrillation), the dose of warfarin can be reduced 4 to 5 days
in advance of surgery to allow the INR to fall to normal or
near normal (1.3 to 1.5) at the time of surgery. The
maintenance dose of warfarin is resumed postoperatively
and supplemented with low-dose heparin (5000 U) or
LMWH administered subcutaneously every 12 hours, if
necessary.
● Finally, for patients undergoing dental procedures, tranex-
amic acid or -aminocaproic acid mouthwash can be
applied without interrupting anticoagulant therapy
(175,176).
Anticoagulation During Pregnancy
Oral anticoagulants cross the placenta and can produce a
characteristic embryopathy with first-trimester exposure and,
less commonly, central nervous system abnormalities and
fetal bleeding with exposure after the first trimester (17). For
this reason, it has been recommended that warfarin therapy be
avoided during the first trimester of pregnancy and, except in
special circumstances, avoided entirely throughout preg-
nancy. Because heparin does not cross the placenta, it is the
preferred anticoagulant in pregnant women. Several reports
of heparin failure resulting in serious maternal consequences
involving patients with mechanical heart valves, however
(170,177,178), have caused some authorities to recommend
that warfarin be used preferentially in women with mechan-
ical prosthetic valves during the second and third trimesters
of pregnancy. It even has been suggested that the inadequacy
of heparin for prevention of maternal thromboembolism
might outweigh the risk of warfarin embryopathy during the
first trimester. Although reports of heparin failures in preg-
nant women with mechanical prosthetic valves could reflect
inadequate dosing, it also is possible that heparin is a less
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effective antithrombotic agent than warfarin in patients with
prosthetic heart valves. This notion is supported by recent
experience with LMWH in pregnant women with prosthetic
heart valves. Thus, as described above (see Management of
Anticoagulated Patients Who Require Surgery), the FDA and
Aventis have issued an advisory warning against the use of
Lovenox in pregnant women with mechanical prosthetic heart
valves. This warning was based on a randomized trial
comparing enoxaparin to warfarin in pregnant patients with
prosthetic heart valves. In contrast to the reported problems of
using heparin or LMWH in pregnant patients with mechani-
cal prosthetic valves, Montalescot and associates (179) re-
ported that LMWH produced safe and effective anticoagula-
tion when given for an average of 14.1 days to 102
nonpregnant patients with mechanical prosthetic heart valves.
Nevertheless, it should be emphasized that LMWH is not
approved by the FDA for use in any patients with mechanical
prosthetic heart valves.
Given the potential medico-legal implications in the United
States of using warfarin during pregnancy, the FDA warning
related to the use of Lovenox, and the reported lack of
efficacy of heparin in pregnant patients with mechanical
prosthetic valves, physicians managing these patients are
faced with a real dilemma. Three options are available. These
are to use: (1) heparin or LMWH throughout pregnancy; (2)
warfarin throughout pregnancy, changing to heparin or
LMWH at 38 weeks’ gestation with planned labor induction
at 40 weeks; or (3) heparin or LMWH in the first trimester
of pregnancy, switching to warfarin in the second trimester,
continuing it until 38 weeks’ gestation, and then changing
to heparin or LMWH at 38 weeks with planned labor
induction at 40 weeks. If heparin or LMWH is used in
pregnant women with mechanical prosthetic valves, they
should be administered in adequate doses and monitored
carefully. Heparin should be given subcutaneously twice
daily, starting at a total daily dose of 35 000 U. Monitoring
should be performed at least twice weekly with either
activated partial thromboplastin time or heparin assays, and
higher heparin requirements should be anticipated in the third
trimester because of an increase in heparin-binding proteins.
LMWH should be given subcutaneously in a dose of 100
anti-Xa U/kg twice daily and the dose adjusted to maintain
the anti-Xa level between 0.5 and 1.0 U/mL 4 to 6 hours after
injection. Heparin or LMWH should be discontinued 12
hours before planned induction of labor. Heparin or LMWH
should be started postpartum and overlapped with warfarin
for 4 to 5 days. There is convincing evidence that, when
administered to a nursing mother, warfarin does not induce an
anticoagulant effect in the breast-fed infant (180,181).
Nonhemorrhagic Adverse Effects of Warfarin
Other than hemorrhage, the most important side effect of
warfarin is skin necrosis. This uncommon complication
usually is observed on the third to eighth day of therapy
(182,183) and is caused by extensive thrombosis of venules
and capillaries within subcutaneous fat. The pathogenesis of
this striking complication is uncertain. An association be-
tween warfarin-induced skin necrosis and protein C defi-
ciency (184–186) and, less commonly, protein S deficiency
(187) has been reported, but warfarin-induced skin necrosis
also occurs in patients without these deficiencies. A patho-
genic role for protein C deficiency is supported by the
similarity of the necrotic lesions to those of neonatal purpura
fulminans, which complicates homozygous protein C defi-
ciency. Patients with coumarin-induced skin necrosis who
require further anticoagulant therapy are problematic. Warfa-
rin is considered contraindicated, and long-term treatment
with heparin is inconvenient and associated with osteoporo-
sis. A reasonable approach is to restart warfarin at a low dose
(eg, 2 mg daily), while therapeutic doses of heparin are
administered concurrently, and gradually increase warfarin
over several weeks. This approach should avoid an abrupt fall
in protein C levels before reduction in levels of factors II, IX,
and X occurs, and several case reports have suggested that
warfarin can be resumed in this way without recurrence of
skin necrosis (184,185).
Clinical Applications of Oral
Anticoagulant Therapy
The clinical effectiveness of oral anticoagulants has been
established by well-designed clinical trials in a variety of
disease conditions. Oral anticoagulants are effective for
primary and secondary prevention of venous thromboembo-
lism, for prevention of systemic embolism in patients with
prosthetic heart valves or atrial fibrillation, for prevention of
acute myocardial infarction (AMI) in patients with peripheral
arterial disease and in men otherwise at high risk, and for
prevention of stroke, recurrent infarction, or death in patients
with AMI (64). Although effectiveness has not been proved
by a randomized trial, oral anticoagulants also are indicated
for prevention of systemic embolism in high-risk patients
with mitral stenosis and in patients with presumed systemic
embolism, either cryptogenic or in association with a patent
foramen ovale. For most of these indications, a moderate
anticoagulant intensity (INR 2.0 to 3.0) is appropriate.
Although anticoagulants are sometimes used for secondary
prevention of cerebral ischemia of presumed arterial origin
when antiplatelet agents have failed, the Stroke Prevention in
Reversible Ischemia Trial (SPIRIT) study found high-
intensity oral anticoagulation (INR 3.0 to 4.5) dangerous in
such cases (121). The trial was stopped at the first interim
analysis of 1316 patients with a mean follow-up of 14 months
because there were 53 major bleeding complications during
anticoagulant therapy (27 intracranial, 17 fatal) versus 6 on
aspirin (3 intracranial, 1 fatal). The authors concluded that
oral anticoagulants are not safe when adjusted to a targeted
INR range of 3.0 to 4.5 in patients who have experienced
cerebral ischemia of presumed arterial origin. In a second
study (the Warfarin Aspirin Recurrent Stroke Study
[WARSS]) (187a), 2206 patients with noncardioembolic
ischemic stroke were randomly assigned to receive either
low-intensity warfarin (INR 1.4 to 2.8) or aspirin (325 mg/d).
The primary end point of death or recurrent ischemic stroke
occurred 17.8 patients assigned to warfarin and 16.0 assigned
to aspirin (P0.25). The rates of major bleeding were 2.2%
and 1.5% in the warfarin and aspirin groups, respectively (not
significant). Thus, low-intensity warfarin and aspirin exhibit
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similar efficacy and safety in patients with noncardioembolic
ischemic stroke.
Prevention of Venous Thromboembolism
Oral anticoagulants when given at a dose sufficient to
maintain an INR between 2.0 and 3.0 are effective for
prevention of venous thrombosis after hip surgery (188–190)
and major gynecologic surgery (191,192). The risk of clini-
cally important bleeding at this intensity is modest. A very
low fixed dose of warfarin (1 mg daily) prevented subclavian
vein thrombosis in patients with malignancy who had in-
dwelling catheters (193). In contrast, 4 randomized trials
found this dose of warfarin ineffective for preventing post-
operative venous thrombosis in patients undergoing major
orthopedic surgery (194–197). Levine and associates (198)
reported that warfarin, 1 mg daily for 6 weeks followed by
adjustment to a targeted INR of 1.5, prevented thrombosis in
patients with stage 4 breast cancer receiving chemotherapy.
In general, when warfarin is used to prevent venous throm-
boembolism, the targeted INR should be 2.0 to 3.0.
Treatment of Deep Venous Thrombosis or
Pulmonary Embolism
The optimum duration of oral anticoagulant therapy is influ-
enced by the competing risks of bleeding and recurrent
venous thromboembolism. The risk of major bleeding during
oral anticoagulant therapy is 3% per year with an annual
case fatality rate of 0.6%. On the other hand, the case
fatality rate from recurrent venous thromboembolism is 5%
to 7%, with the rate being higher in patients with pulmonary
embolism. Therefore, at an annual recurrence rate of 12%, the
risk of death from recurrent thromboembolism is balanced by
the risk of death from anticoagulant-related bleeding. The risk
of recurrent thromboembolism when anticoagulant therapy is
discontinued depends on whether thrombosis is unprovoked
(idiopathic) or is secondary to a reversible cause; a longer
course of therapy is warranted when thrombosis is idiopathic
or associated with a continuing risk factor (199). The reported
risk of recurrence in patients with idiopathic proximal vein
thrombosis has been reported to be between 10% and 27%
when anticoagulants are discontinued after 3 months. Extend-
ing therapy beyond 6 months seems to reduce the risk of
recurrence to 7% during the year after treatment is discon-
tinued (200).
Patients should be treated with anticoagulants for a mini-
mum of 3 months. Moderate-intensity anticoagulation (INR
2.0 to 3.0) is as effective as a more intense regimen (INR 3.0
to 4.5) but is associated with less bleeding (166). Treatment
should be longer in patients with proximal vein thrombosis
than in those with distal thrombosis and in patients with
recurrent thrombosis versus those with an isolated episode.
Laboratory evidence of thrombophilia also may warrant a
longer duration of anticoagulant therapy, according to the
nature of the defect. Oral anticoagulant therapy is indicated
for 3 months in patients with proximal deep vein thrombo-
sis (201,202), for 6 months in those with proximal vein
thrombosis in whom a reversible cause cannot be identified
and eliminated or in patients with recurrent venous thrombo-
sis, and for 6 to 12 weeks in patients with symptomatic calf
vein thrombosis (203–205). Indefinite anticoagulant therapy
should be considered in patients with 1 episode of idio-
pathic proximal vein thrombosis, thrombosis complicating
malignancy, or idiopathic venous thrombosis and homozy-
gous factor V Leiden genotype, the antiphospholipid antibody
syndrome, or deficiencies of antithrombin III, protein C, or
protein S (206–208). Prospective cohort studies indicate that
heterozygous factor V Leiden or the G20210A prothrombin
gene mutation in patients with idiopathic venous thrombosis
does not increase the risk of recurrence (207,209).
These recommendations are based on results of random-
ized trials (207) that demonstrated that oral anticoagulants
effectively prevent recurrent venous thrombosis (risk reduc-
tion 90%), that treatment for 6 months is more effective
than treatment for 6 weeks (206), and that treatment for 2
years is more effective than treatment for 3 months (208).
Primary Prevention of Ischemic Coronary Events
The Thrombosis Prevention Trial (64) evaluated warfarin
(target INR 1.3 to 1.8), aspirin (75 mg/d), both, or neither in
5499 men aged 45 to 69 years at risk of a first myocardial
infarction (MI). The primary outcome was acute myocardial
ischemia, defined as coronary death or nonfatal MI. Although
the anticoagulant intensity was low, the mean warfarin dose
was 4.1 mg/d. The annual incidence of coronary events was
1.4% per year in the placebo group, whereas the combination
of warfarin and aspirin reduced the relative risk by 34%
(P0.006). Given separately, neither warfarin nor aspirin
produced a significant reduction in acute ischemic events, and
the efficacy of the 2 drugs was similar (relative risk reduc-
tions 22% and 23% with warfarin and aspirin, respectively).
The combined treatment, though most effective, was associ-
ated with a small but significant increase in hemorrhagic
stroke. These results suggest that, in the primary prevention
setting, low-intensity warfarin anticoagulation targeting an
INR of 1.3 to 1.8 is effective for prevention of acute ischemic
events (particularly fatal events) and that the combination of
low-intensity warfarin plus aspirin is more effective than
either agent alone, at the price of a small increase in bleeding.
Despite its effectiveness, low-intensity warfarin is not
preferred over aspirin for primary prophylaxis in high-risk
patients because warfarin requires INR monitoring and is
associated with greater potential for bleeding.
The effectiveness of the combination of low-intensity
warfarin plus aspirin in the Thrombosis Prevention Trial (64)
contrasts with the results of the Coumadin Aspirin Reinfarc-
tion Study (CARS) (210), Stroke Prevention in Atrial Fibril-
lation (SPAF) III trial (124), and Post Coronary Artery
Bypass Graft (Post-CABG) (211) study, in which this type of
combination therapy was ineffective. In the Thrombosis
Prevention Trial, the dose of warfarin was adjusted between
0.5 and 12.5 mg/d (INR of 1.3 to 1.8), whereas in the CARS
and SPAF III studies, warfarin was given in fixed doses. The
reason for the contrasting effectiveness of low-intensity
warfarin in these primary and secondary prevention situations
is not clear.
Acute Myocardial Infarction
Initial evidence supporting use of oral anticoagulants in
patients with AMI dates to the 1960s and 1970s, when
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warfarin given in moderate intensity (estimated INR of 1.5 to
2.5) was found effective for prevention of stroke and pulmo-
nary embolism (212–216). Of 3 randomized trials in which
the effectiveness of oral anticoagulants was evaluated in
patients with AMI (213–215), 2 (213,215) showed a signifi-
cant reduction in stroke but no significant impact on mortal-
ity, whereas there was a reduction in mortality in the third
(214). In all 3 studies, the incidence of clinically diagnosed
pulmonary embolism was reduced. Effectiveness of oral
anticoagulants in the long-term management of patients with
AMI was supported by the results of a meta-analysis of data
pooled from 7 randomized trials published between 1964 and
1980, which showed that oral anticoagulants reduced the
combined end points of mortality and nonfatal reinfarction by
20% during treatment periods of between 1 and 6 years
(215–217).
Subsequently, a higher INR was evaluated in several
European studies. The Sixty-Plus Re-infarction Study in-
cluded patients 60 years of age who had been treated with
oral anticoagulants for 6 months; lower rates of reinfarction
and stroke were observed in patients randomized to continue
anticoagulant therapy than in those from whom anticoagula-
tion was withdrawn (218). As a treatment-interruption trial in
a select age group, the findings were of limited generalizabil-
ity. In another study with no age restriction (the WArfarin
Re-Infarction Study [WARIS]), Smith and associates (219)
reported a 50% reduction in the combined outcomes of
recurrent infarction, stroke, and mortality. Similarly, the
Anticoagulants in the Secondary Prevention of Events in
Coronary Thrombosis (ASPECT) trial (119), which also had
no age restriction, reported 50% reduction in reinfarction
and a 40% reduction in stroke among survivors of MI. Each
of these studies (119,218,219) used high-intensity warfarin
regimens (INR 2.7 to 4.5 in the Sixty-Plus Study and 2.8 to
4.8 in the WARIS and ASPECT studies); each found the
incidence of bleeding was increased with anticoagulants.
More recently, several studies have evaluated different
intensities of anticoagulation, either alone or in combination
with aspirin (Tables 4 and 5). The ASPECT II study com-
pared warfarin alone (goal INR 3.0 to 4.0) with aspirin (80
mg daily) and with the combination of aspirin (80 mg daily)
plus warfarin (INR 2.0 to 2.5) in 993 patients after an acute
coronary syndrome. The sponsor halted the study because of
slow recruitment when the composite end point of death, MI,
and stroke occurred in 9.0% of patients on aspirin alone, 5.0%
of those on warfarin alone, and 5.0% of those on the
combined regimen. There was an excess of minor bleeding in
those on the combination of warfarin (INR 2.0 to 2.5) and
aspirin (220) In the Antithrombotics in the Prevention of
Reocclusion In COronary Thrombolysis (APRICOT) II study
(221) of 308 patients with TIMI grade 3 coronary flow after
thrombolysis for ST segment–elevation MI, aspirin (160 mg
initially followed by 80 mg daily) was compared with aspirin
in the same dosage combined with warfarin (INR 2.0 to 3.0)
to assess the 3-month rate of angiographic reocclusion.
Reocclusion occurred in 30% of the group given aspirin alone
compared with 18% in those given aspirin plus warfarin
(relative risk 0.60; 95% CI 0.39 to 0.93). There was an
increase in minor but not major bleeding in the combination
group (221). The WARIS II trial (222) compared warfarin or
aspirin or both in 3630 patients 75 years of age with AMI
randomized at the time of hospital discharge and followed up
for 2 years for the first occurrence of the composite of
all-cause death, nonfatal reinfarction, or thromboembolic
stroke. This composite end point occurred in 20% of the
patients on aspirin alone (160 mg/d), 16.7% of those on
TABLE 4. Randomized Trials in MI Comparing ASA, the Combination of ASA and Moderate- or Low-Intensity Warfarin, and
High-Dose Warfarin: Efficacy
Study (No. of patients;
follow-up period)
Acute Coronary
Syndromes Patients
Efficacy
Outcome
ASA
Efficacy Outcome, %
(Dose)
OA INR Plus ASA
Efficacy Outcome, %
(Dose) OA INR
ASPECT II119 (n993; 26 mo) MI Death, MI, stroke 9.0% (80 mg) 5.0% 2.0–2.5 (80 mg) 5.0% 3.0–4.0
WARIS II222 (n3630; 48 mo) MI Death, MI, stroke 20% (160 mg) 16.7% 2.0–2.5 (75 mg) 15.0% 2.8–4.2
APRICOT 2221 (n308; 3 mo) MI (All received
thrombolytic therapy)
Reocclusion at 3 mo 30% (80 mg,160 mg) 18% 2.0–3.0 (80 mg,160 mg)   
CARS210 (n8803; 14 mo) MI Death, MI, stroke 8.6% (160 mg) 8.4% warfarin 3 mg (80 mg)   
CHAMP223 (n5059; 31 mo) MI Death, MI, stroke 33.9% (162 mg) 34% 1.5–2.5 (81 mg)   
OA indicates oral anticoagulation.
TABLE 5. Randomized Trials in MI Comparing ASA, the Combination of ASA and Moderate- or Low-Intensity Warfarin, and
High-Dose Warfarin: Bleeding
Study (No. of patients;
follow-up period)
Acute Coronary
Syndromes Patients Bleeding ASA OA Plus ASA OA (High Intensity)
ASPECT II119 (n993; 26 mo) MI Major 0.9% 2.1% 0.9%
WARIS II222 (n3630; 48 mo) MI Major 0.15% per y 0.58% per y 0.52% per y
APRICOT 2221 (n308; 3 mo) MI All received
thrombolytic therapy
Total 3% 5%
CARS210 (n8803; 14 mo) MI Spontaneous 0.74% 1.4%
OA indicates oral anticoagulation.
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warfarin alone (mean INR 2.8), and 15% of those on the
combination of both drugs (mean INR 2.2; aspirin 75 mg/d).
Odds ratios for the combined end point were 0.71 for the
combination of warfarin plus aspirin versus aspirin alone
(95% CI 0.58 to 0.86; P0.0005), 0.81 for warfarin alone
versus aspirin alone (95% CI 0.67 to 0.98; P0.028), and
0.88 for the combination versus warfarin alone (95% CI 0.72
to 1.07; P0.20). The superiority of the combination over
aspirin was highly significant at P0.0005, but there was no
significant difference between the 2 warfarin groups. Major
bleeding occurred at a rate of 0.15% per year in the aspirin-
alone group, 0.58% per year in the warfarin-alone group, and
0.52% per year in the combination group (222).
Two studies, CARS (210) and the Combined Hemotherapy
And Mortality Prevention Study (CHAMP) (223), compared
aspirin alone with the combination of aspirin and low-
intensity warfarin (lower limit of targeted INR 2.0). The
CARS study in 8803 patients with AMI showed that low
fixed-dose warfarin (1 or 3 mg/d) plus aspirin (80 mg) was no
more effective than aspirin alone (160 mg) for the long-term
treatment of survivors of MI (209). Thus, after a mean of 14
months of follow-up, the incidence of death, recurrent MI, or
stroke was 8.6 in the aspirin group and 8.4 in the combination
of aspirin and warfarin (3 mg/d) group. Despite the lack of
increased efficacy, the combined aspirin and warfarin (3
mg/d) group showed an increase in major bleeding. The
CHAMP study (223) was an open-label trial that evaluated
the relative efficacy and safety of aspirin alone (162 mg/d)
and the combination of warfarin (INR 1.5 to 2.5) and aspirin
(81 mg/d) in 5059 patients with AMI. There was no differ-
ence in total mortality (17.3% versus 17.3%), in nonfatal MI
(13.1% versus 13.3%), or in nonfatal stroke (4.7% versus
4.2%). Despite lack of increased efficacy, major bleeding was
more common in the combined treatment group.
Indirect support for the efficacy of oral anticoagulants in
patients with coronary artery disease also comes from a
randomized trial of patients with peripheral arterial disease
(224). A relatively high-intensity oral anticoagulant regimen
(INR 2.6 to 4.5) produced a significant 51% reduction in
mortality (from 6.8% to 3.3% per year) compared with an
untreated control group (P0.023).
A meta-analysis of 31 randomized trials of oral anticoag-
ulant therapy published between 1960 and 1999 involving
patients with coronary artery disease treated for 3 months,
stratified by the intensities of anticoagulation and aspirin
therapy, is shown in Table 6. High-intensity (INR 2.8 to 4.8)
and moderate-intensity (INR 2 to 3) oral anticoagulation
regimens reduced the rates of MI and stroke but increased the
risk of bleeding 6.0- to 7.7-fold. When combined with
aspirin, low-intensity anticoagulation (INR 2.0) was not
superior to aspirin alone, whereas moderate- to high-intensity
oral anticoagulation and aspirin versus aspirin alone seemed
promising. There was a modest increase in the bleeding risk
associated with the combination (225).
Because a rebound increase in ischemic events has been
documented after discontinuation of heparin (226) and
LMWH (227,228), the use of oral anticoagulants to prevent
reinfarction has been evaluated in several studies. The ische-
mic event rate was reduced by 65% after 6 months in one
study of 102 patients (P0.05) (229). In the Antithrombotic
Therapy in Acute Coronary Syndromes (ATACS) trial (230),
the combined rate of death, MI, and recurrent ischemia
decreased from 27.5% to 10.5% after 2 weeks with an INR of
2.0 to 2.5 in 214 patients (P0.004), but most of the benefit
accrued during the earlier phase of heparin therapy. The
Organization to Assess Strategies for Ischemic Syndromes
(OASIS) (231) pilot study of hirudin versus heparin found a
dose-adjusted warfarin regimen (INR 2 to 2.5) superior to a
fixed dose (3 mg daily) over 6 months in 506 patients, all of
whom were given aspirin concurrently. The 58% difference
in the rate of death, MI, or refractory angina was marginally
significant, but fewer patients were hospitalized for unstable
angina (P0.03).
From the results of these clinical trials, conclusions can be
drawn about long-term treatment of patients with acute
myocardial ischemia: (1) High-intensity oral anticoagulation
(INR 3.0 to 4.0) is more effective than aspirin but is
associated with more bleeding; (2) the combination of aspirin
and moderate-intensity warfarin (INR 2.0 to 3) is more
effective than aspirin but is associated with a greater risk of
bleeding; (3) the combination of aspirin and moderate-
intensity warfarin (INR 2.0 to 3.0) is as effective as high-
intensity warfarin and is associated with a similar risk of
bleeding; (4) the contemporary trials have not addressed the
effectiveness of moderate-intensity warfarin (INR 2.0 to 3.0),
and in the absence of direct evidence, it cannot be assumed
that moderate-intensity warfarin is any more effective than
aspirin in preventing death or reinfarction; and (5) there is no
evidence that the combination of aspirin and low-intensity
TABLE 6. Risk-Benefit Assessment of Oral Anticoagulant Therapy in Patients With Coronary Artery
Disease: Meta-Analysis of 44 Trials Involving 24 115 Patients*
Anticoagulation Intensity
No. of Trials
(No. of Patients)
Ischemic Events
Odds Ratio
(95% CI) P
Major Bleeding
Odds Ratio P
High vs control 16 (n10 056) 0.57 (0.51–0.63) 0.0001 39 0.00001
Moderate vs control 4 (n1365) 0.85 (0.80–1.34) 0.10 35 0.00001
Moderate to high vs ASA 7 (n3457) 0.88 (0.63–1.24) 0.10 14 0.00001
Moderate  ASA vs ASA 3 (n480) 0.44 (0.23–0.83) 0.01 16 0.01
Low  ASA vs ASA 3 (n8435) 0.91 (0.79–1.06) 0.01 5 0.05
*Constellation of death, myocardial infarction, or stroke events per 1000 patients.
Adapted from Anand and Yusuf, 1999.225
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warfarin (INR 2.0) is more effective than aspirin alone,
despite the fact that the combination produces more bleeding.
Therefore, the choice for long-term management involves
aspirin alone, aspirin plus moderate-intensity warfarin (INR
2.0 to 3.0), or high-intensity warfarin (INR 3.0 to 4.0). The
latter 2 regimens are more effective than aspirin but are
associated with more bleeding and are much less convenient
to administer. Furthermore, in the absence of tight INR
control, the high-intensity regimen has the potential to cause
unacceptable bleeding. An alternative approach to long-term
antithrombotic management of patients with acute myocar-
dial ischemia is to use a combination of aspirin plus clopi-
dogrel. Recommendations of the choice among these com-
peting approaches is beyond the scope of this review on oral
anticoagulants but should be addressed in future recommen-
dations for the management of patients with acute myocardial
ischemia.
Prosthetic Heart Valves
The most convincing evidence that oral anticoagulants are
effective in patients with prosthetic heart valves comes from
a study of patients randomized to receive warfarin in uncer-
tain intensity versus either of 2 aspirin-containing platelet-in-
hibitor drug regimens for 6 months (232). The incidence of
thromboembolic complications in the group that continued
warfarin was significantly lower than that of the groups that
received antiplatelet drugs (relative risk reduction 60% to
79%). The incidence of bleeding was highest in the warfarin
group. Three studies addressed the minimum effective inten-
sity of anticoagulant therapy. One study of patients with
bioprosthetic heart valves found a moderate dose regimen
(INR 2.0 to 2.25) as effective as a more intense regimen (INR
2.5 to 4.0) but associated with less bleeding (167). A second
study (168), involving patients with mechanical prosthetic
heart valves, found no difference in effectiveness between a
very high-intensity regimen (INR 7.4 to 10.8) and a lower-
intensity regimen (INR 1.9 to 3.6), but the higher-intensity
regimen produced more bleeding. Another study (169) of
patients with mechanical prosthetic valves treated with aspi-
rin and dipyridamole found no difference in efficacy between
moderate-intensity (INR 2.0 to 3.0) and high-intensity (INR
3.0 to 4.5) warfarin regimens, but more bleeding occurred
with the high-intensity regimen. A more recent randomized
trial showed that addition of aspirin (100 mg/d) to warfarin
(INR 3.0 to 4.5) improved efficacy compared with warfarin
alone (63). This combination of low-dose aspirin and high-
intensity warfarin was associated with a reduction in all-cause
mortality, cardiovascular mortality, and stroke at the expense
of increased minor bleeding; the difference in major bleeding,
including cerebral hemorrhage, did not reach statistical sig-
nificance. A retrospective study of 16 081 patients with
mechanical heart valves in the Netherlands attending 4
regional anticoagulation clinics (target INR 3.6 to 4.8) found
a sharp rise in the incidence of embolic events when the INR
fell to 2.5, whereas bleeding increased when the INR rose
to 5.0 (120).
Guidelines developed by the European Society of Cardiol-
ogy (233) called for anticoagulant intensity in proportion to
the thromboembolic risk associated with specific types of
prosthetic heart valves. For first-generation valves, an INR of
3.0 to 4.5 was recommended. An INR of 3.0 to 3.5 was
considered sensible for second-generation valves in the mitral
position, whereas an INR of 2.5 to 3.0 was deemed sufficient
for second-generation valves in the aortic position. The
American College of Chest Physicians guidelines (234) of
2001 recommended an INR of 2.5 to 3.5 for most patients
with mechanical prosthetic valves and of 2.0 to 3.0 for those
with bioprosthetic valves and low-risk patients with bileaflet
mechanical valves (such as the St Jude Medical device) in the
aortic position. Similar guidelines have been promulgated
conjointly by the American College of Cardiology and the
American Heart Association (235). In contrast, a higher upper
limit of the therapeutic range (INR 4.8 to 5.0) has been
recommended by some European investigators (118,236).
Management of women with prosthetic heart valves during
pregnancy and the potential shortcomings of heparin and
LMWH in such patients have been discussed in the section on
pregnancy.
Atrial Fibrillation
Five trials with relatively similar study designs have ad-
dressed anticoagulant therapy for primary prevention of
ischemic stroke in patients with nonvalvular (nonrheumatic)
atrial fibrillation. The SPAF study (237), the Boston Area
Anticoagulation Trial for Atrial Fibrillation (BAATAF)
(238), and the Stroke Prevention In Nonvalvular Atrial
Fibrillation (SPINAF) trial were carried out in the United
States (239); the Atrial Fibrillation, Aspirin, Anticoagulation
study (AFASAK) was carried out in Denmark (240); and the
Canadian Atrial Fibrillation Anticoagulation (CAFA) study
(241) was stopped before completion because of convincing
results in 3 of the other trials (242). In the AFASAK and
SPAF trials, patients also were randomized to aspirin therapy
(238,241). The results of all 5 studies were similar; pooled
analysis on an intention-to-treat basis showed a 69% risk
reduction and 80% risk reduction in patients who remained
on treatment with warfarin (efficacy analysis) (243). There
was little difference between rates of major or intracranial
hemorrhage in the warfarin and control groups, but minor
bleeding was 3% per year more frequent in the warfarin-
assigned groups (244). Pooled results from 2 studies were
consistent with a smaller benefit from aspirin. In the
AFASAK study, 75 mg daily did not significantly reduce
thromboembolism, whereas in the SPAF trial, 325 mg per day
was associated with a 44% stroke risk reduction in younger
patients.
A secondary prevention trial in Europe (the European
Atrial Fibrillation Trial [EAFT]) (245) compared anticoagu-
lant therapy, aspirin, and placebo in patients with atrial
fibrillation who had sustained nondisabling stroke or transient
ischemic attack within 3 months. Compared with placebo,
there was a 68% reduction in stroke with warfarin and an
insignificant 16% stroke risk reduction with aspirin. None of
the patients in the anticoagulant group suffered intracranial
hemorrhage.
The SPAF II (246) trial compared the efficacy and safety of
warfarin with aspirin in patients with atrial fibrillation.
Warfarin was more effective than aspirin for preventing
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ischemic stroke, but this difference was almost entirely offset
by a higher rate of intracranial hemorrhage with warfarin,
particularly among patients 75 years of age, in whom the
rate of intracranial hemorrhage was 1.8% per year. The
intensity of anticoagulation was greater in the SPAF trials
than in several of the other primary prevention studies; in
addition, the majority of intracranial hemorrhages during
these trials occurred when the estimated INR was3.0. In the
SPAF III study (124), warfarin (INR 2.0 to 3.0) was much
more effective than a fixed-dose combination of warfarin (1
to 3 mg/d; INR 1.2 to 1.5) plus aspirin (325 mg/d) in high-risk
patients with atrial fibrillation, whereas aspirin alone was
sufficient for patients at low intrinsic risk of thromboembo-
lism. Whether treatment targeted to the lower end of the
therapeutic INR range (near 2) provides much, if not all, the
benefit achieved remains to be evaluated in a prospective trial
(123). In a Dutch general practice population without estab-
lished indications for warfarin, neither low- nor standard-
intensity anticoagulation was better than aspirin in preventing
ischemic events (247).
In summary, the evidence indicates that both warfarin and
aspirin are effective for prevention of systemic embolism in
patients with nonvalvular atrial fibrillation. Warfarin is more
effective than aspirin but is associated with a higher rate of
bleeding. As might be expected, randomized trials involving
high-risk atrial fibrillation patients (stroke rates 6% per
year) show larger absolute risk reductions by adjusted-dose
warfarin relative to aspirin, whereas the absolute risk reduc-
tions are consistently smaller in trials of atrial fibrillation
patients with lower stroke rates. Warfarin, adjusted to achieve
an INR of 2 to 3, is therefore most advantageous (from the
perspective of benefit versus risk) for patients at greatest
intrinsic risk. Subgroup analysis of the atrial fibrillation
studies identified the following high-risk features: prior
stroke or thromboembolism, age 65 years, hypertension,
diabetes mellitus, coronary arterial disease, and moderate to
severe left ventricular dysfunction by echocardiography (Fig-
ure 2) (173).
American College of Cardiology/American Heart Associ-
ation/European Society of Cardiology guidelines for the
management of patients with atrial fibrillation were published
in 2001 (248).
Other Indications for Oral Anticoagulant Therapy
Other widely accepted indications for oral anticoagulant
therapy have not been evaluated in properly designed clinical
trials. Among these are atrial fibrillation associated with
valvular heart disease, and mitral stenosis in the presence of
sinus rhythm. Long-term anticoagulation (INR 2.0 to 3.0)
also is indicated in patients who have sustained one or more
episodes of systemic thromboembolism. Anticoagulants are
not presently indicated in patients with ischemic cerebrovas-
cular disease (249,250). Reduced left ventricular systolic
function is associated with both stroke and mortality even in
the absence of documented atrial fibrillation (251). Warfarin
is used frequently in patients with dilated cardiomyopathy,
although no randomized trials have confirmed the benefit of
anticoagulation (252). Long-term anticoagulant therapy also
is indicated in patients with ischemic stroke of unknown
origin who have a combination of a patent foramen ovale and
atrial septal aneurysm because these patients have an in-
creased the risk of recurrent stroke despite treatment with
aspirin (253).
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